Hematology

Patients with multiple myeloma are potentially at greater risk of developing severe COVID-19 after the SARS-COv-2 vaccination induced suboptimal antibody response.

A recent study showed that belumosudil induced clinically meaningful, durable responses among a varied cohort of patients with chronic graft-versus-host-disease.

More data are needed regarding the duration of response associated with this combination to make it a “mainstream” treatment option for patients, according to an expert from the University of Michigan Rogel Cancer Center.

The combination of ficlatuzumab and chemotherapy demonstrated some promising results in a small group of patients with relapsed/refractory acute myeloid leukemia.

Data from a 5-year follow-up study confirmed that CPX-351 continues to be associated with long-term remission and improved overall survival compared to 7+3 chemotherapy in certain older patients with acute myeloid leukemia.

Thomas G. Martin, MD, discusses the results of the IKEMA study and the future of isatuximab combination.

Anakinra prophylaxis was associated with lower incidences of ≥2 grade cytokine release syndrome and no adverse effects on the incidence of neurological events in patients with multiple myeloma.

Despite relatively good cardiovascular health, a significant percentage of patients with MPN were not prescribed appropriate medication.

Symptomatic iron deficiency, a key challenge in facing polycythemia vera, might be effectively treated with rusfertide.

Treating patients with relapsed/refractory multiple myeloma with Talquetamab at RP2D elicits high clinical response rate.

Data presented at the European Hematology Association 2021 Virtual Meeting revealed that CAR T-cell therapy-related adverse effects can be managed.

“We've had to develop a unique process and a unique cryo buffer that allows us to freeze natural killer cells and recover greater than 90% of those cells. So, the new GDA-201 cryo-preserved is now going to be an off-the-shelf product and we're going to reinstitute a multicenter study in lymphoma to include both histologies of follicular lymphoma and diffuse large B cell lymphoma.”

A retrospective cohort study found that convalescent plasma treatment resulted in a meaningful improvement in the 30-day mortality rate for patients with hematologic cancer and COVID-19.

“So, what we’ve done is develop a technique, using the NAM technology, to expand those stem cells, so we can make 50 to 100-fold more stem cells, with higher reliability, and manufacture those cells for patients in need of a bone marrow transplant”

The efficacy of CYNK-001 will now be studied with patients with relapsed/refractory AML.

The phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials reported that Week 24 transfusion independence resulted in an improved overall survival for patients with myelofibrosis.

An early trial evaluated Anti-C-type lectin-like molecule-1 (CLL-1)-based CAR T cells for its safety and efficacy in improving the symptoms of pediatric patients with acute myeloid leukemia (AML).

A virtual presentation at the 2021 American Society of Clinical Oncology Annual Meeting suggested that patients with B-ALL benefit from single infusions of KTE-X19 (Tecartus).

Consider options like prophylactic medications and optimal fluid administration when giving a 4-drug regimen to treat patients with multiple myeloma, one expert says.

The FDA approved avapritinib (Ayvakit) for the treatment of adults with advanced systemic mastocytosis (AdvSM), including those with mast cell leukemia (MCL), aggressive systemic mastocytosism (ASM), or systemic mastocytosis with an associated hematological neoplasm (SM-AHN).

Discrepancies exist between actual patterns of care and recommendations based on clinical trials in adult patients with mantle cell lymphoma.

Learn how to approach palliative care discussions with both physicians and patients.

The second-generation 4-1BB bi-specific CAR T-cell therapy was efficacious and safe in treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Survival rates were similar between the 2 drugs, but acalabrutinib had fewer adverse events.

The FDA has granted a breakthrough therapy designation to teclistamab for the treatment of patients with relapsed/refractory multiple myeloma.

Age was associated with overall survival and the time to Richter transformation in adolescent and young adult patients with chronic lymphocytic leukemia, according to findings from a single-institutional, retrospective study.

Melphalan flufenamide was noninferior to pomalidomide in patients with relapsed or refractory myeloma.

The FDA has granted priority review to the biologics license application for ciltacabtagene autoleucel for the treatment of patients with relapsed/refractory multiple myeloma.

The FDA has accepted a biologics license application for ublituximab in combination with umbralisib in the treatment of patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

Adding the antibody-drug conjugate to the frontline treatment of patients with pediatric high-risk Hodgkin lymphoma resulted in favorable clinical outcomes.